Risk Factors for Bleeding Varicose Veins in Patients with Chronic Venous Disease

Abstract

Background and Objectives: Chronic venous disease (CVD) is a widespread clinical condition that is very common in western countries in the adult general population with a wide range of clinical manifestations, such as varicose veins (VVs) that in certain circumstances may complicate with rupture and subsequent bleeding that may even be fatal. The aim of this study is to evaluate risk factors for bleeding VVs. Materials and Methods: This is a retrospective study conducted in patients with CVD complicating with bleeding of VVs over a 4-year period (2019–2022). A random sample, for the same 4-year period and with a 3:1 ratio, was selected from other CVD patients without VVs bleeding that served as the control group. Results: From a global population of 1048 patients with CVD over a 4-year period, a total of 33 patients (3.15%) with VVs bleeding were selected. A group of 99 patients without VVs bleeding were randomly selected from the total population of 1048 patients with CVD. Findings of this study showed that advanced clinical stage of CVD (i.e., C4b stage), advanced age, living alone, suffering from cardiovascular co-morbidity (i.e., hypertension and CHF), assuming certain drugs that act on blood coagulation (i.e., aspirin, anticoagulants), assuming psychotropic medication, having particular venous reflux patterns (i.e., below-knee GSV reflux, non-saphenous veins reflux, Cockett’s perforators reflux), and not having been assessed and treated previously for CVD (i.e., with VADs, CT, or surgery) may predispose a high risk for bleeding VVs. Conclusions: Bleeding VVs may be a life-threatening complications of CVD patients, and monitoring risk factors found in this study and others that, hopefully, may be discovered in the future through further focused research will help to reduce the impact of this problem in this patient population.

Transcatheter Arterial Embolization (TAE) of Cancer-Related Bleeding

“…Continuous data are reported as previously described [ 29 , 30 ]. The unpaired Student’s t -test [ 31 ], the chi-squared/Fisher’s exact tests, and the Wilcoxon rank-sum test [ 32 , 33 ] were performed as appropriate. For the tests stated above, a p -value of 0.05 was considered statistically significant.…”

Transcatheter Arterial Embolization (TAE) in the Management of Bleeding in the COVID-19 Patient

“…The data’s assumed normality was checked using the Kolmogorov–Smirnov and Shapiro–Wilk tests. Frequency (% value) is the presentation format for categorical data [ 46 ]. Data with a continuous normal distribution are shown as mean ± standard deviation.…”

A Multicenter Retrospective Cohort Study Evaluating the Clinical Outcomes of Patients with Coagulopathy Undergoing Transcatheter Arterial Embolization (TAE) for Acute Non-Neurovascular Bleeding

“…Continuous not normally distributed data are presented as medians (first–third quartile) [ 63 , 64 , 65 ]. The unpaired Student’ t -test was used to assess statistical differences for continuous normally distributed data [ 66 ], whereas categorical and continuous not normally distributed data were assessed using the Chi-squared/Fisher’s exact tests and the Mann–Whitney test, respectively [ 67 , 68 ]. A p -value of <0.05 was considered statistically significant for the aforementioned tests.…”